Solid Biosciences Inc. (SLDB)
| Market Cap | 213.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.44M |
| Shares Out | 39.95M |
| EPS (ttm) | -2.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 188,781 |
| Open | 5.60 |
| Previous Close | 5.79 |
| Day's Range | 5.21 - 5.72 |
| 52-Week Range | 3.11 - 15.05 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+227.72%) |
| Earnings Date | Nov 6, 2024 |
About SLDB
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which help... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 227.72% from the latest price.
News
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 ...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscula...
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 202...
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardia...
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 —
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024....
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., Ap...
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 202...
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs mark...
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genet...
Solid Biosciences Announces $109 Million Private Placement
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, toda...
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, toda...
Solid Biosciences Provides Third Quarter Business Update and Financial Results
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with...
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromus...
Solid Biosciences Provides Second Quarter Business Update and Financial Results
– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) –
Solid Biosciences to Participate at the Jefferies Healthcare Conference
CHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announce...
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
CHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with ...
Solid Biosciences Provides First Quarter Business Update and Financial Results
– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) –
Solid Biosciences to Present at JMP Securities Life Sciences Conference
CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced...
Solid Biosciences to Participate in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announc...
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announ...